Findings

What do systematic reviews say?

57 questions · 61 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 4.9%GRADE not reported 1 · 1.6%Very low 1 · 1.6%Low 23 · 37.7%Moderate 25 · 41%High 8 · 13.1%

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

RAP · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

Cardiac index · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

PVR · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

All‐cause mortality · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i leads to lower mortality compared with placebo (high certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 0.22 [0.07, 0.68]
8 studies · 1119 participants
High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

QoL · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 163 participants
GRADE not reported

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

PAP · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 453 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

RAP · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 341 participants
High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

Cardiac index · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 239 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

PVR · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 266 participants
High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

Improvement in WHO functional class · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with placebo, on combination therapy (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 1.2 [0.66, 2.17]
2 studies · 227 participants
Moderate

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

Improvement in WHO functional class · people with pulmonary hypertension group 2 ‐ 4

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i probably leads to higher improvement in WHO functional class compared with placebo (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 11.31 [4.9, 26.14]
2 studies · 146 participants
Moderate

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

Six‐minute walk distance · people with pulmonary hypertension group 2 ‐ 4

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 106 participants
Moderate

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

All‐cause mortality · people with pulmonary hypertension group 2 ‐ 4

The review found no eligible studies for this question.

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

Quality of life · people with pulmonary hypertension group 2 ‐ 4

The review found no eligible studies for this question.

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

PASP · people with pulmonary hypertension group 2 ‐ 4

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 146 participants
Moderate

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

Improvement in WHO functional class · people with pulmonary hypertension due to CTEPH

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with placebo (low certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 17.18 [0.78, 380.84]
1 study · 19 participants
Low

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

Six‐minute walk distance · people with pulmonary hypertension due to CTEPH

2 findings from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low
Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 227 participants
Moderate

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

Mortality ‐ sildenafil versus placebo · people with pulmonary hypertension due to CTEPH

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

Mortality ‐ sildenafil versus bosentan · people with pulmonary hypertension due to CTEPH

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i showed no clear difference in mortality ‐ sildenafil versus bosentan compared with placebo (low certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 1.36 [0.22, 8.48]
1 study · 106 participants
Low

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

Quality of life · people with pulmonary hypertension due to CTEPH

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low